✦ LIBER ✦

A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma : Cancer and Leukemia Group B study 9181

✍ Scribed by Nancy A. Dawson; Mark Conaway; Susan Halabi; Eric P. Winer; Eric J. Small; Diana Lake; Nicholas J. Vogelzang

Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 105 KB
Volume: 88
Category: Article
ISSN: 0008-543X
DOI: 10.1002/(sici)1097-0142(20000215)88:4<825::aid-cncr13>3.0.co;2-n

No coin nor oath required. For personal study only.

✦ Synopsis

BACKGROUND.

Megestrol acetate (MA) is a synthetic progestin with reported activity in both hormone-sensitive and hormone-refractory prostate carcinoma (HRPC). Based on limited data suggesting a possible dose-response effect, a trial was initiated to compare standard versus moderately high dose MA in HRPC.